DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
RONACALERET
2
Small molecule
Investigational
Unknown
Unknown
Fractures, Bone; Osteoporosis
Calcium sensing receptor antagonist
RONACALERET
×
Maximum Phase:
2
First Approval:
None
UNII:
DIH95YP7J3
Molecule Type:
Small molecule
Molecular Formula:
C25H31F2NO4
Molecular Weight:
447.52
AlogP:
3.9
PSA:
78.79
HBD:
3.0
HBA:
#RotB:
11.0
Source:
TOLUENE
2
Small molecule
Investigational
Unknown
Unknown
Hot Flashes
Unknown
TOLUENE
×
Maximum Phase:
2
First Approval:
None
UNII:
3FPU23BG52
Molecule Type:
Small molecule
Molecular Formula:
C7H8
Molecular Weight:
92.14
AlogP:
2.0
PSA:
0.0
HBD:
0.0
HBA:
#RotB:
0.0
Source:
TEDATIOXETINE
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
Alpha-1a adrenergic receptor antagonist
TEDATIOXETINE
×
Maximum Phase:
2
First Approval:
None
UNII:
5H681S8O3S
Molecule Type:
Small molecule
Molecular Formula:
C18H21NS
Molecular Weight:
283.44
AlogP:
4.61
PSA:
12.03
HBD:
1.0
HBA:
#RotB:
3.0
Source:
MK-0873
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis; Arthritis, Rheumatoid; Lung Diseases; Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitor
MK-0873
×
Maximum Phase:
2
First Approval:
None
UNII:
K4KAC9XCCO
Molecule Type:
Small molecule
Molecular Formula:
C25H18N4O3
Molecular Weight:
422.44
AlogP:
2.31
PSA:
90.93
HBD:
1.0
HBA:
#RotB:
3.0
Source:
GW842166X
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis; Osteoarthritis, Knee; Pain
Cannabinoid CB2 receptor agonist
GW842166X
×
Maximum Phase:
2
First Approval:
None
UNII:
VL1I6P2DZ8
Molecule Type:
Small molecule
Molecular Formula:
C18H17Cl2F3N4O2
Molecular Weight:
449.26
AlogP:
4.7
PSA:
76.14
HBD:
2.0
HBA:
#RotB:
5.0
Source:
LY2157299
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LY2157299
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANOXERINE
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders; Atrial Flutter; Atrial Fibrillation
Unknown
VANOXERINE
×
Maximum Phase:
2
First Approval:
None
UNII:
90X28IKH43
Molecule Type:
Small molecule
Molecular Formula:
C28H32F2N2O
Molecular Weight:
450.57
AlogP:
5.32
PSA:
15.71
HBD:
0.0
HBA:
#RotB:
10.0
Source:
REMETINOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, T-Cell, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell
Unknown
REMETINOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
37NT056AT4
Molecule Type:
Small molecule
Molecular Formula:
C16H21NO6
Molecular Weight:
323.35
AlogP:
2.22
PSA:
101.93
HBD:
2.0
HBA:
#RotB:
9.0
Source:
PF-03049423
2
Small molecule
Investigational
Unknown
Unknown
Ischemic Stroke
Phosphodiesterase 5A inhibitor
PF-03049423
×
Maximum Phase:
2
First Approval:
None
UNII:
9CZX3Z9945
Molecule Type:
Small molecule
Molecular Formula:
C24H32N6O4
Molecular Weight:
468.56
AlogP:
1.4
PSA:
105.84
HBD:
1.0
HBA:
#RotB:
10.0
Source:
LTX-109
2
Small molecule
Investigational
Unknown
Unknown
Hidradenitis Suppurativa; Impetigo; Severe Acute Respiratory Syndrome; Staphylococcal Infections
Cell membrane disrupting agent
LTX-109
×
Maximum Phase:
2
First Approval:
None
UNII:
HO813QDF65
Molecule Type:
Small molecule
Molecular Formula:
C43H69N11O3
Molecular Weight:
788.1
AlogP:
3.79
PSA:
252.91
HBD:
11.0
HBA:
#RotB:
18.0
Source:
SSR125543
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SSR125543
×
Maximum Phase:
2
First Approval:
None
UNII:
MFT24BX55I
Molecule Type:
Small molecule
Molecular Formula:
C27H28ClFN2OS
Molecular Weight:
483.05
AlogP:
7.52
PSA:
25.36
HBD:
0.0
HBA:
#RotB:
8.0
Source:
BOSWELLIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Multiple Sclerosis, Relapsing-Remitting
Unknown
BOSWELLIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
B252M1YO2V
Molecule Type:
Small molecule
Molecular Formula:
C30H48O3
Molecular Weight:
456.71
AlogP:
7.09
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
1.0
Source:
MENAQUINONE 7
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MENAQUINONE 7
×
Maximum Phase:
2
First Approval:
None
UNII:
8427BML8NY
Molecule Type:
Small molecule
Molecular Formula:
C46H64O2
Molecular Weight:
649.02
AlogP:
14.1
PSA:
34.14
HBD:
0.0
HBA:
#RotB:
20.0
Source:
O-(2-FLUOROETHYL)-L-TYROSINE F-18
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
O-(2-FLUOROETHYL)-L-TYROSINE F-18
×
Maximum Phase:
2
First Approval:
None
UNII:
1326R5J1IA
Molecule Type:
Small molecule
Molecular Formula:
C11H14FNO3
Molecular Weight:
226.24
AlogP:
0.99
PSA:
72.55
HBD:
2.0
HBA:
#RotB:
6.0
Source:
CLEMIZOLE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Carcinoma, Hepatocellular; Lennox Gastaut Syndrome
Unknown
CLEMIZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
T97CB3796L
Molecule Type:
Small molecule
Molecular Formula:
C19H20ClN3
Molecular Weight:
325.84
AlogP:
4.33
PSA:
21.06
HBD:
0.0
HBA:
#RotB:
4.0
Source:
VESNARINONE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
VESNARINONE
×
Maximum Phase:
2
First Approval:
None
UNII:
5COW40EV8M
Molecule Type:
Small molecule
Molecular Formula:
C22H25N3O4
Molecular Weight:
395.46
AlogP:
2.55
PSA:
71.11
HBD:
1.0
HBA:
#RotB:
4.0
Source:
RALFINAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Pain
Glutamate [NMDA] receptor antagonist
RALFINAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
3LPF0S0GVV
Molecule Type:
Small molecule
Molecular Formula:
C17H19FN2O2
Molecular Weight:
302.35
AlogP:
2.37
PSA:
64.35
HBD:
2.0
HBA:
#RotB:
7.0
Source:
LY3023414
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LY3023414
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-256066
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic, Seasonal
Phosphodiesterase 4 inhibitor
GSK-256066
×
Maximum Phase:
2
First Approval:
None
UNII:
2D6GK059SR
Molecule Type:
Small molecule
Molecular Formula:
C27H26N4O5S
Molecular Weight:
518.6
AlogP:
3.93
PSA:
131.69
HBD:
2.0
HBA:
#RotB:
7.0
Source:
CERLAPIRDINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Serotonin 6 (5-HT6) receptor antagonist
CERLAPIRDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
EK40PJ0V49
Molecule Type:
Small molecule
Molecular Formula:
C22H23N3O3S
Molecular Weight:
409.51
AlogP:
3.88
PSA:
75.29
HBD:
1.0
HBA:
#RotB:
7.0
Source:
GSK3117391
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GSK3117391
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XRP9881
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
XRP9881
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BUTYLATED HYDROXYTOLUENE
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
Unknown
BUTYLATED HYDROXYTOLUENE
×
Maximum Phase:
2
First Approval:
None
UNII:
1P9D0Z171K
Molecule Type:
Small molecule
Molecular Formula:
C15H24O
Molecular Weight:
220.36
AlogP:
4.3
PSA:
20.23
HBD:
1.0
HBA:
#RotB:
0.0
Source:
ULODESINE
2
Small molecule
Investigational
Unknown
Unknown
Gout; Hyperuricemia; Osteoarthritis
Purine nucleoside phosphorylase inhibitor
ULODESINE
×
Maximum Phase:
2
First Approval:
None
UNII:
JNG8L9460Y
Molecule Type:
Small molecule
Molecular Formula:
C12H16N4O3
Molecular Weight:
264.29
AlogP:
-0.96
PSA:
105.24
HBD:
4.0
HBA:
#RotB:
3.0
Source:
MIFAMURTIDE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Osteosarcoma
Nucleotide-binding oligomerization domain-containing protein 2 other
MIFAMURTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1LM890Q4FY
Molecule Type:
Small molecule
Molecular Formula:
C59H109N6O19P
Molecular Weight:
1237.52
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
RILAPLADIB
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Atherosclerosis
LDL-associated phospholipase A2 inhibitor
RILAPLADIB
×
Maximum Phase:
2
First Approval:
None
UNII:
O14CWE893Z
Molecule Type:
Small molecule
Molecular Formula:
C40H38F5N3O3S
Molecular Weight:
735.82
AlogP:
8.4
PSA:
54.78
HBD:
0.0
HBA:
#RotB:
12.0
Source:
BECLOMETHASONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BECLOMETHASONE
×
Maximum Phase:
2
First Approval:
None
UNII:
KGZ1SLC28Z
Molecule Type:
Small molecule
Molecular Formula:
C22H29ClO5
Molecular Weight:
408.92
AlogP:
2.17
PSA:
94.83
HBD:
3.0
HBA:
#RotB:
2.0
Source:
DOXYCYCLINE FOSFATEX
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DOXYCYCLINE FOSFATEX
×
Maximum Phase:
2
First Approval:
None
UNII:
2IQ26U2DZQ
Molecule Type:
Small molecule
Molecular Formula:
C22H27N2NaO20P4
Molecular Weight:
786.34
AlogP:
-0.35
PSA:
181.62
HBD:
6.0
HBA:
#RotB:
2.0
Source:
MEVIDALEN
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Parkinson Disease; Lewy Body Disease
Dopamine D1 receptor positive allosteric modulator
MEVIDALEN
×
Maximum Phase:
2
First Approval:
None
UNII:
4A3702A96F
Molecule Type:
Small molecule
Molecular Formula:
C24H29Cl2NO3
Molecular Weight:
450.41
AlogP:
4.75
PSA:
60.77
HBD:
2.0
HBA:
#RotB:
6.0
Source:
BELORANIB
2
Small molecule
Investigational
Unknown
Unknown
Obesity; Prader-Willi Syndrome
Methionine aminopeptidase 2 inhibitor
BELORANIB
×
Maximum Phase:
2
First Approval:
None
UNII:
FI471K8BU6
Molecule Type:
Small molecule
Molecular Formula:
C29H41NO6
Molecular Weight:
499.65
AlogP:
4.26
PSA:
73.06
HBD:
0.0
HBA:
#RotB:
11.0
Source:
BEFIRADOL
2
Small molecule
Investigational
Unknown
Unknown
Movement Disorders
Serotonin 1a (5-HT1a) receptor agonist
BEFIRADOL
×
Maximum Phase:
2
First Approval:
None
UNII:
RAT9OHA1YH
Molecule Type:
Small molecule
Molecular Formula:
C20H22ClF2N3O
Molecular Weight:
393.87
AlogP:
3.92
PSA:
45.23
HBD:
1.0
HBA:
#RotB:
5.0
Source:
PELITINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Rectal Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
PELITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
X5DWL380Z6
Molecule Type:
Small molecule
Molecular Formula:
C24H23ClFN5O2
Molecular Weight:
467.93
AlogP:
5.1
PSA:
90.28
HBD:
2.0
HBA:
#RotB:
8.0
Source:
GSK-364735
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 integrase inhibitor
GSK-364735
×
Maximum Phase:
2
First Approval:
None
UNII:
SXN0KXT60S
Molecule Type:
Small molecule
Molecular Formula:
C19H18FN3O4
Molecular Weight:
371.37
AlogP:
1.09
PSA:
104.45
HBD:
3.0
HBA:
#RotB:
5.0
Source:
ABT-639
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia
Voltage-gated T-type calcium channel alpha-1H subunit blocker
ABT-639
×
Maximum Phase:
2
First Approval:
None
UNII:
0G7D0CQ88I
Molecule Type:
Small molecule
Molecular Formula:
C20H20ClF2N3O3S
Molecular Weight:
455.91
AlogP:
3.34
PSA:
69.72
HBD:
1.0
HBA:
#RotB:
4.0
Source:
POLIFEPROSAN 20
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms
Unknown
POLIFEPROSAN 20
×
Maximum Phase:
2
First Approval:
None
UNII:
S40C40DA21
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
100
101
102
103
104
105
106
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA